AVIS FAVORABLE DU CMUH CONCERNANT UNE UTILISATION PLUS LARGE DE REPATHA® D'AMGEN POUR REDUIRE LES RISQUES DE PREMIER INFARCTUS DU MYOCARDE OU D'AVC

RegulatoryRepathaPositive

AI Analysis

Summary

Amgen's Repatha received a favorable opinion from CMUH for expanded use in reducing the risk of first myocardial infarction and stroke. Repatha is the only PCSK9 inhibitor with demonstrated efficacy for this indication in a Phase III clinical trial.

Clinical Trial Data

Phase

Phase_3

Primary Endpoint

Met

Outcome Details

Favorable opinion from CMUH for broader use of Repatha

Importance:7/10

Sentiment:

0.80

PCSK9_inhibitorcardiovascularregulatory_approvalefficacy

Related Companies

$AMGN

Read the original article

Published by PR Newswire Biotech on July 30, 2026 4:45 PM

Read Original